Anavex Q2 Loss Narrows to $5.3M, Cash Runway Extended to 2028
AVXL is trading near its 52-week low of $2.255 (10.0% above the low).
Summary
Anavex reported a narrower Q2 net loss of $5.3M ($0.06/share) driven by lower R&D spending after completing the ANAVEX 3-71 schizophrenia trial. The company now expects its cash balance to fund operations into mid-to-late fiscal 2028, a significant extension that reduces near-term dilution risk. This follows a turbulent period including the CEO's termination for cause in April, a Nasdaq delinquency notice, and a proxy fight launched by PVG Asset Management to replace the board. The improved cash runway and cost discipline offer a stabilizing signal amid governance turmoil. Upcoming catalysts include initiation of an ADME study for early Alzheimer's in Q3 2026 and planned FDA engagement on clinical strategy for Alzheimer's and Fragile X.
At the time of this announcement, AVXL was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.8M. The 52-week trading range was $2.26 to $12.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.